January 24, 2017 9:45 PM ET

Pharmaceuticals

Company Overview of Zydus Pharmaceuticals (USA) Inc.

Company Overview

Zydus Pharmaceuticals (USA) Inc. operates as a generic pharmaceutical company that discovers, develops, manufactures, and markets various healthcare therapies/generic pharmaceutical products to customers in the United States. The company was incorporated in 2003 and is based in Pennington, New Jersey. Zydus Pharmaceuticals (USA) Inc. operates as a subsidiary of Cadila Healthcare Limited.

73 Route 31 North

Suite 103

Pennington, NJ 08534

United States

Founded in 2003

Phone:

609-730-1900

Fax:

609-730-1998

Key Executives for Zydus Pharmaceuticals (USA) Inc.

Chief Executive Officer, President and Chief Executive Officer of Zydus Pharmaceuticals
Compensation as of Fiscal Year 2016.

Zydus Pharmaceuticals (USA) Inc. Key Developments

Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. Announces Settlement of Patent Litigation with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd

Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. announced that they have finalized as agreement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. To settle all outstanding patent litigation related to Livalo (potavastatin calcium) tablets. Under the terms of the agreement, Kowa and Nissan grants Zydus a license to Zydus’ generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances.

Cadila Healthcare and Zydus Pharmaceuticals (USA) Settle Patent Litigation with Upsher-Smith Laboratories

Cadila Healthcare and its subsidiary Zydus Pharmaceuticals (USA) have finalized an agreement with Upsher-Smith Laboratories, to settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules. Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus' generic version of Qudexy XR beginning on March 19, 2020, or earlier under certain circumstances.

Allergan plc and Qualicaps Co., Ltd. Announce Settlement with Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Limited

Allergan plc and its subsidiaries announced that they, along with Qualicaps Co., Ltd., have reached a settlement regarding their litigation with Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Limited relating to United States Patent No. 6,649,180 and Allergan's DELZICOL (mesalamine) product. As a result of the settlement, and if approved by FDA, Zydus and Cadila may be able to market their generic version of DELZICOL® in the United States beginning on March 1, 2020, or earlier under certain circumstances.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zydus Pharmaceuticals (USA) Inc., please visit www.zydususa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.